PE20221413A1 - Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas - Google Patents

Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas

Info

Publication number
PE20221413A1
PE20221413A1 PE2022000588A PE2022000588A PE20221413A1 PE 20221413 A1 PE20221413 A1 PE 20221413A1 PE 2022000588 A PE2022000588 A PE 2022000588A PE 2022000588 A PE2022000588 A PE 2022000588A PE 20221413 A1 PE20221413 A1 PE 20221413A1
Authority
PE
Peru
Prior art keywords
chemokine
receptor
humanized antibodies
therapeutic applications
antibodies anti
Prior art date
Application number
PE2022000588A
Other languages
English (en)
Inventor
Vanessa Gauttier
Nicolas Poirier
Caroline Mary
Charlène Trilleaud
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19306323.7A external-priority patent/EP3804754A1/en
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of PE20221413A1 publication Critical patent/PE20221413A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion proporciona compuestos humanizados anti-CMKLR1 que tienen una capacidad agonista en la interaccion entre Resolvina E1 y CMKLR1, y sus usos para tratar o prevenir una enfermedad, en particular en la que la resolucion de la inflamacion se retrasa o se interrumpe.
PE2022000588A 2019-10-09 2020-10-09 Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas PE20221413A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306323.7A EP3804754A1 (en) 2019-10-09 2019-10-09 Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications
EP19306322 2019-10-09
PCT/EP2020/078488 WO2021069709A1 (en) 2019-10-09 2020-10-09 Anti-chemokin like receptor 1 humanized antibodies and their therapeutic applications

Publications (1)

Publication Number Publication Date
PE20221413A1 true PE20221413A1 (es) 2022-09-20

Family

ID=72811872

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000588A PE20221413A1 (es) 2019-10-09 2020-10-09 Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas

Country Status (13)

Country Link
US (1) US20240084019A1 (es)
EP (1) EP4041302A1 (es)
JP (1) JP2022552490A (es)
KR (1) KR20220087466A (es)
CN (1) CN114786722A (es)
AU (1) AU2020365034A1 (es)
CA (1) CA3156835A1 (es)
CO (1) CO2022004545A2 (es)
CR (1) CR20220155A (es)
IL (1) IL292029A (es)
MX (1) MX2022004312A (es)
PE (1) PE20221413A1 (es)
WO (1) WO2021069709A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024028508A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis
WO2024028509A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Treatment of an inflammation-associated disease in a patient expressing high chemerin level

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
US20050202029A1 (en) * 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
US8038992B2 (en) * 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
WO2012172336A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory skin diseases
AU2019247068A1 (en) * 2018-04-03 2020-10-22 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibodies and their therapeutic applications

Also Published As

Publication number Publication date
CO2022004545A2 (es) 2022-07-08
KR20220087466A (ko) 2022-06-24
IL292029A (en) 2022-06-01
WO2021069709A1 (en) 2021-04-15
JP2022552490A (ja) 2022-12-16
MX2022004312A (es) 2022-08-16
AU2020365034A1 (en) 2022-04-21
US20240084019A1 (en) 2024-03-14
CN114786722A (zh) 2022-07-22
CA3156835A1 (en) 2021-04-15
EP4041302A1 (en) 2022-08-17
CR20220155A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
CL2018003563A1 (es) Anticuerpos anti-c5 y usos de los mismos.
ECSP21025707A (es) Anticuerpos estabilizadores de trem2
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
MX2020004556A (es) Moduladores de la vía de estrés integrada.
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
DOP2021000064A (es) Moduladores de profámacos de la vía de estrés integrada
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
PE20221413A1 (es) Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
CL2020001391A1 (es) Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CO2021007006A2 (es) Moduladores de la expresión de irf5
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
BR112022000855A2 (pt) Moduladores de nlrp3
CO2022014499A2 (es) Moduladores de nlrp3
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
CU20210028A7 (es) Anticuerpos estabilizadores de trem2